Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History IPHA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics IPHA

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Innate Pharma

IPHA
Current price
1.80 USD -0.0027 USD (-0.15%)
Last closed 1.77 USD
ISIN US45781K2042
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 171 866 912 USD
Yield for 12 month -18.18 %
1Y
3Y
5Y
10Y
15Y
IPHA
21.11.2021 - 28.11.2021

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France. Address: 117, Avenue de Luminy, Marseille, France, 13009

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

7.86 USD

P/E Ratio

Dividend Yield

Financials IPHA

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures IPHA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+14 752 552 USD

Last Year

+60 666 524 USD

Current Quarter

+322 613 USD

Last Quarter

+14 429 939 USD

Current Year

+14 752 552 USD

Last Year

-4 816 993 USD

Current Quarter

+34 309 239 USD

Last Quarter

-19 556 687 USD
EBITDA -50 274 000 USD
Operating Margin TTM -324.87 %
Price to Earnings
Return On Assets TTM -22.52 %
PEG Ratio
Return On Equity TTM -162.91 %
Wall Street Target Price 7.86 USD
Revenue TTM 20 121 000 USD
Book Value 0.11 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -63.70 %
Dividend Yield
Gross Profit TTM -31 859 000 USD
Earnings per share -0.72 USD
Diluted Eps TTM -0.72 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY -74.70 %
Profit Margin -245.87 %

Stock Valuation IPHA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 7.24
Price Sales TTM 8.54
Enterprise Value EBITDA -6.94
Price Book MRQ 15.29

Technical Indicators IPHA

For 52 Weeks

1.29 USD 3.51 USD
50 Day MA 2.05 USD
Shares Short Prior Month 51 456
200 Day MA 1.96 USD
Short Ratio 3.95
Shares Short 60 667
Short Percent 0.060 %